TransMedics Group, Inc.
NASDAQ:TMDX · NASDAQ Global Market
+$5.94 today
Vol 1.72M · Avg 1.32M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
40.2%
avg 30.7%
ROIC
10.9%
avg -27.7%
ROA
17.8%
avg -23.2%
Analysis
ROE is currently the strongest return metric at 40.2% versus its period average of 30.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Waleed H. Hassanein | Founder, President, Chief Executive Officer & Director | $2.19M | — | 58 | $495,009.00 | 1.43% |
Tamer I. Khayal | Senior Vice President of International | $1.04M | — | 57 | $36,042.00 | 0.10% |
Gerardo Hernandez | Chief Financial Officer & Treasurer | $1.03M | — | 55 | $20,601.00 | 0.06% |
Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | $865,837.00 | — | 44 | $29,831.00 | 0.09% |
Anil Ranganath | Advisor | $634,758.00 | — | 44 | $13,091.00 | 0.04% |
Matthew Forsyth | Senior Vice President, General Counsel & Corporate Secretary | $594,250.00 | — | — | $23,171.00 | 0.07% |
Miriam C. Provost | Vice President of Global Regulatory Affairs | $535,930.00 | — | 65 | $23,348.00 | 0.07% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$2.98M
Sells
12
$5.20M
Net Sentiment
$2.22M
Net selling
Most Active
Hassanein Waleed H
4 transactions
1–10 of 16
Analysis
Insiders reported 4 buys worth $2.98M and 12 sells worth $5.20M over the last 12 months. That adds up to net selling of $2.22M. Hassanein Waleed H was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +49.4% | +53.5% (9yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +49.4% over three years. Forward estimates point to Revenue at +53.5% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Bruker Corporation
NASDAQ:BRKR
$8.56B
Glaukos Corporation
NYSE:GKOS
$7.69B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.45B
Oscar Health, Inc.
NYSE:OSCR
$7.32B
Immunovant, Inc.
NASDAQ:IMVT
$7.14B
Hinge Health, Inc.
NYSE:HNGE
$5.24B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.78B
Akero Therapeutics, Inc.
AKRO
$4.50B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.48B
Option Care Health, Inc.
NASDAQ:OPCH
$3.45B
Who manages TMDX?
TransMedics Group, Inc. (TMDX) lists 7 active executives. The top listed executive is Tamer I. Khayal, Senior Vice President of International.
Are TMDX insiders buying or selling?
Recent insider activity shows net selling of $9.76M.
Explore More
Continue the stock analysis
Jump to another research area for this company.